Conditionally immortalized embryonic rat hippocampal H19-7 cells have been described previously (Eves et al., 1992) .
were done on rounded-up cells that had been treated with Taxol.
Immunocytochemistry and Immunoblotting
Cultured cells were fixed with 4% paraformaldehyde in 0.1M phosphate buffer (pH=7.4), permeabilized with 0.1% Triton X-100, blocked overnight at 4°C in 5% IgGfree BSA in PBS and exposed to primary antibody in 1% BSA in PBS for 2 hrs at room temperature(RT). Cells were exposed to secondary antibodies for 1.5 -2 hrs (RT).. See
For immunoblots, cells were lysed with RIPA buffer, equal amounts of protein were separated on 8.5%, 10% or 12.5% polyacrylamide gels, transferred to nitrocellulose membranes and immunoblotted as previously described (Corbit et al., 2003) . Bands were developed with Perkin Elmer Western Lightening and exposed to film, or quantified using the FluorChem8000 system (Alpha Innotech).
Polyclonal RKIP and phosphoS153RKIP (pRKIP) antibodies were described previously (Corbit et al., 2003) . A monoclonal antibody to the C-terminus of human RKIP was purchased from Zymed. Antibodies to α-tubulin (sc-8035) and cyclin B1 (sc-245) were from Santa Cruz Biotechnology. The phosphoHistone H3 (08-570), p338Raf-1 (05-538), and pCENP-A antibodies (05-792, 07-232) were from Upstate Biotechnology. The anti-phosphoAurora B (pT232) was from Rockland. pERK and pMEK antibodies were from Cell Signaling. Nek2 (N521-20) antibodies were obtained from BD Transduction Laboratories. Survivin antibodies (AF886) were from R&D Systems. CENP-A antibodies were from MBL International. The 3F3/2 antibody was described previously (Cyert et al., 1988) . Aurora B antibodies were the gift of Stephen Taylor (Univ. of Manchester, UK), or purchased from BD Transduction Laboratories (611082). Antiserum to human centromeres (CREST/ACA) was the gift of William C.
Earnshaw (University of Edinburgh, Scotland).
In Vitro Kinase Assays and Aurora Kinase Inhibition
For Aurora B kinase assays cells were lysed with 20 mM Tris, pH 7.5, 250 mM NaCl, 2mM EGTA, 1mM DTT, 1% Triton X-100, 20mM ß-glycerophosphate, 1 mM NaF and a protease inhibitor cocktail (Roche). The extract was precleared with Protein G sepharose beads for 30 minutes at 4 o C. Aurora B was immunoprecipitated from 20 mg of whole cell protein with 2.5 µg monoclonal AIM-1 anti-Aurora B antibody bound to
Protein G sepharose at 4 o C for 90 minutes. Beads were washed, aliquoted and washed in kinase buffer (20mM Tris, pH 7.5, 150 mM NaCl, 10 mM MgCl 2 , 1 mM DTT, 10 mM NaF) and assayed. The Aurora kinase inhibitor ZM447439 (AstraZeneca, UK, Ltd.) was used to identify non-specific kinase activity; concentrations of 0.5 to 10 µM were added to HeLa cells for 0-3 hours to determine effective levels and treatment times.
Image Acquisition and Quantitation
Time-lapse images were acquired at 3 min intervals by a Princeton Instruments MicroMAX 1300Y cooled CCD camera with SlideBook (Intelligent Imaging Innovations).
In deconvolved images for kinetochore or chromatin associated markers the entire chromatin region was outlined and total pixel intensity quantified. Non-cellular background pixel intensities were measured on the same slides and subtracted. Images were acquired with a Leica DMIRB microscope equipped with a QImaging
